164 related articles for article (PubMed ID: 35240257)
41. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Sun W; Zeng C; Liao L; Chen J; Wang Y
Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
[TBL] [Abstract][Full Text] [Related]
42. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
43. Exploring metformin monotherapy response in Type-2 diabetes: Computational insights through clinical, genomic, and proteomic markers using machine learning algorithms.
Villikudathil AT; Mc Guigan DH; English A
Comput Biol Med; 2024 Mar; 171():108106. PubMed ID: 38368755
[TBL] [Abstract][Full Text] [Related]
44. Association of SLC22A1 rs622342 and ATM rs11212617 polymorphisms with metformin efficacy in patients with type 2 diabetes.
Chen P; Cao Y; Guo Y; Xu Q; Wang X; Zhang L; Liu Z; Chen D; Chen S; Chen S
Pharmacogenet Genomics; 2022 Feb; 32(2):67-71. PubMed ID: 34545025
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.
Singh S; Shukla AK; Usman K; Banerjee M
Pharmacogenet Genomics; 2023 Apr; 33(3):51-58. PubMed ID: 36853844
[TBL] [Abstract][Full Text] [Related]
47. Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States.
Fernandes G; Sawhney B; Hannachi H; Liu J; Wang T; Fu AZ; Iglay K; McNeill A; Rajpathak S
Curr Med Res Opin; 2020 May; 36(5):741-748. PubMed ID: 31990206
[No Abstract] [Full Text] [Related]
48. Clinical Study on the Relationship between the SNP rs8192675 (C/C) Site of SLC2A2 Gene and the Hypoglycemic Effect of Metformin in Type 2 Diabetes.
Ye W; Wang Y; Chen F; Zhao Q; Meng X; Chen J; Liu C; Zhou Y
J Healthc Eng; 2022; 2022():3645336. PubMed ID: 35140900
[TBL] [Abstract][Full Text] [Related]
49. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
Gavin LA; Barth J; Arnold D; Shaw R
Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
[TBL] [Abstract][Full Text] [Related]
51. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol.
Mato EPM; Guewo-Fokeng M; Faadiel Essop M; Owira PMO
Syst Rev; 2018 Jul; 7(1):105. PubMed ID: 30041690
[TBL] [Abstract][Full Text] [Related]
52. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
[TBL] [Abstract][Full Text] [Related]
53. A Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients.
Park JE; Jeong GH; Lee IK; Yoon YR; Liu KH; Gu N; Shin KH
Molecules; 2018 Jun; 23(7):. PubMed ID: 29966242
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
Mokta JK; Ramesh ; Sahai AK; Kaundal PK; Mokta K
J Assoc Physicians India; 2018 Aug; 66(8):30-35. PubMed ID: 31324081
[TBL] [Abstract][Full Text] [Related]
55. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
[TBL] [Abstract][Full Text] [Related]
56. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
58. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
Rajpathak SN; Rajgopalan S; Engel SS
J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
[TBL] [Abstract][Full Text] [Related]
59. No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives.
Martono DP; Heerspink HJL; Hak E; Denig P; Wilffert B
Diabetes Obes Metab; 2019 Oct; 21(10):2267-2273. PubMed ID: 31168905
[TBL] [Abstract][Full Text] [Related]
60. Genome-Wide Association Study Identifies Pharmacogenomic Variants Associated With Metformin Glycemic Response in African American Patients With Type 2 Diabetes.
Wu B; Yee SW; Xiao S; Xu F; Sridhar SB; Yang M; Hochstadt S; Cabral W; Lanfear DE; Hedderson MM; Giacomini KM; Williams LK
Diabetes Care; 2024 Feb; 47(2):208-215. PubMed ID: 37639712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
